Pandemic preparedness involves comprehensive planning and coordination to mitigate the impact of global health crises caused by infectious diseases. It encompasses strategies at local, national, and international levels to enhance surveillance, response capabilities, and public health infrastructure. Key components of pandemic preparedness include early detection through surveillance systems, rapid response mechanisms, development and stockpiling of vaccines and antiviral medications, and communication strategies to disseminate accurate information to the public. Global organizations, such as the World Health Organization (WHO), play a vital role in coordinating international efforts and providing guidance for pandemic preparedness. Collaborations between governments, public health agencies, research institutions, and pharmaceutical companies are essential to address emerging threats. Lessons learned from previous pandemics, such as the H1N1 influenza pandemic and the COVID-19 pandemic, underscore the need for continuous improvement in preparedness strategies. Ongoing research focuses on developing new technologies, improving vaccine platforms, and refining response protocols to enhance global readiness for potential future pandemics.
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United Kingdom
Elena Chiappini
University of Florence, ItalySubmit your abstract Today
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology Analysis of MPXV and VACV Peptides Underscores the Need to Consider Both MPXV Clades for Vaccine Development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Awareness and acceptability of rotavirus vaccine among mothers of under-five children in Gusau and Bungudu communities of Zamfara state, northwestern Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil